NCT05636215View on ClinicalTrials.gov

A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

368

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

October 31, 2025

Conditions

Locally Advanced Unresectable or Metastatic Solid Tumors

Interventions

BIOLOGICAL

IBI354

Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection

Trial Locations (6)

2031

COMPLETED

Scientia Clinical Research Ltd, Randwick

2145

COMPLETED

Westmead Hospital, Sydney

3168

COMPLETED

Monash Health, Clayton

4575

COMPLETED

Sunshine Coast University Private Hospital, Sunshine Coast

100142

RECRUITING

Peking University Cancer Hospital, Beijing

400030

RECRUITING

Affiliated Cancer Hospital of Chongqing University, Chongqing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT05636215 - A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter